JP2010522185A - 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物 - Google Patents

糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物 Download PDF

Info

Publication number
JP2010522185A
JP2010522185A JP2009554635A JP2009554635A JP2010522185A JP 2010522185 A JP2010522185 A JP 2010522185A JP 2009554635 A JP2009554635 A JP 2009554635A JP 2009554635 A JP2009554635 A JP 2009554635A JP 2010522185 A JP2010522185 A JP 2010522185A
Authority
JP
Japan
Prior art keywords
composition
quercetin
myricetin
chlorogenic acid
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009554635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522185A5 (enExample
Inventor
アーレンズ，ミルトン，ジョセフ
トンプソン，ダリル，リー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ATM METABOLICS LLLP
Original Assignee
ATM METABOLICS LLLP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39590291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010522185(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ATM METABOLICS LLLP filed Critical ATM METABOLICS LLLP
Publication of JP2010522185A publication Critical patent/JP2010522185A/ja
Publication of JP2010522185A5 publication Critical patent/JP2010522185A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009554635A 2007-03-19 2008-03-11 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物 Pending JP2010522185A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89548607P 2007-03-19 2007-03-19
PCT/US2008/056474 WO2008115723A1 (en) 2007-03-19 2008-03-11 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Publications (2)

Publication Number Publication Date
JP2010522185A true JP2010522185A (ja) 2010-07-01
JP2010522185A5 JP2010522185A5 (enExample) 2011-02-03

Family

ID=39590291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009554635A Pending JP2010522185A (ja) 2007-03-19 2008-03-11 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物

Country Status (8)

Country Link
US (2) US7943164B2 (enExample)
EP (1) EP2129371B1 (enExample)
JP (1) JP2010522185A (enExample)
CN (1) CN101674821B (enExample)
BR (1) BRPI0809047B8 (enExample)
CA (1) CA2685031A1 (enExample)
MX (1) MX2009009996A (enExample)
WO (1) WO2008115723A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011001311A (ja) * 2009-06-19 2011-01-06 Pola Chemical Industries Inc 熱産生タンパク質発現促進剤
JP2017105745A (ja) * 2015-12-02 2017-06-15 共栄化学工業株式会社 皮膚外用剤

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685031A1 (en) * 2007-03-19 2008-09-25 Atm Metabolics Lllp Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid
JP5524466B2 (ja) * 2008-10-31 2014-06-18 ユニテックフーズ株式会社 中性風味デザートベース
US20100178413A1 (en) * 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
US9918489B2 (en) * 2008-12-17 2018-03-20 Mark Gorris Food-based supplement delivery system
BR112012002979A2 (pt) * 2009-08-10 2015-09-01 Stokely Van Camp Inc Método para suspensão de um flavonoide em uma bebida
RU2012125881A (ru) 2010-01-29 2014-03-10 Эбботт Лэборетриз Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция)
WO2011094548A1 (en) 2010-01-29 2011-08-04 Abbott Laboratories Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
US8372447B2 (en) * 2010-08-03 2013-02-12 Northern Innovations And Formulations Corp. Compositions and methods for promoting weight loss and increasing energy
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
WO2012114204A2 (en) * 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
EA029002B9 (ru) 2011-06-06 2019-02-28 Унилевер Н.В. Съедобная композиция
EP2726881A1 (en) 2011-06-28 2014-05-07 Koninklijke Philips N.V. Means for the examination of body fluids
CN102772424B (zh) * 2012-06-13 2014-01-08 浙江大学 新橙皮苷在制备防治糖尿病药物中的应用
KR101396059B1 (ko) * 2012-06-25 2014-05-16 중앙대학교 산학협력단 소귀나무잎으로부터 분리된 신규 황산염 페놀성 화합물 및 이의 항산화 및 항염 용도
JP6291491B2 (ja) 2012-06-29 2018-03-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 干渉粒子を含有する流体の処理
JP6297546B2 (ja) 2012-06-29 2018-03-20 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 結合磁性粒子及び未結合磁性粒子の処理
EP2875336B1 (en) 2012-07-18 2017-05-31 Koninklijke Philips N.V. Processing of a sample fluid with target components
WO2014083474A1 (en) 2012-11-30 2014-06-05 Koninklijke Philips N.V. Capture particle for selectively binding a target molecule
CN106456692A (zh) 2014-04-13 2017-02-22 马尔玛投资有限公司 用于降低血糖水平及用于体重管理的膳食组合物
US10307759B2 (en) 2014-06-25 2019-06-04 Koninklijke Philips N.V. Biosensor for the detection of target components in a sample
US20170326194A1 (en) * 2014-12-01 2017-11-16 Cape Kingdom Nutraceuticals (Pty) Ltd Therapeutic compositions
CN107407675B (zh) 2015-03-26 2020-03-17 皇家飞利浦有限公司 生物传感器盒的制造
CN105816473B (zh) * 2015-07-06 2018-04-10 武汉华纳联合药业有限公司 一种黄酮苷类组合物及其制剂和制法
US20180133243A1 (en) * 2016-11-16 2018-05-17 Holista Colltech Ltd Method and composition for crude formulations of fortified sugar for glycemic control
TWI736755B (zh) * 2017-04-03 2021-08-21 大江生醫股份有限公司 包含植物萃取物的組成物及其減少紫外線所致皮膚損傷之用途
WO2020247961A1 (en) * 2019-06-07 2020-12-10 Advanced Delivery Labs Llc Compositions and methods for improving wellness
CN111387504A (zh) * 2020-04-15 2020-07-10 武汉森澜生物科技有限公司 一种含绿原酸和柚皮苷的活性提取物、提取方法及其用途
US20250213519A1 (en) * 2022-03-28 2025-07-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synergy for increasing insulin sensitivity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108627A1 (en) * 2001-09-25 2003-06-12 Jonathan Selzer Cranberry based dietary supplement and dental hygiene product
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134233B2 (ja) 1991-07-26 2001-02-13 株式会社林原生物化学研究所 α−グリコシル ケルセチンとその製造方法並びに用途
AU6765798A (en) * 1997-03-20 1998-10-12 Coventry Group, Ltd. Nutritional supplement for cardiovascular health
US7229651B2 (en) 1997-08-06 2007-06-12 Melaleuca, Inc. Dietary supplements containing natural ingredients
KR20000019716A (ko) 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
US20020068704A1 (en) 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
US20020054924A1 (en) 2000-04-13 2002-05-09 Leahy Margaret M. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
AU2003261903A1 (en) * 2002-11-06 2004-06-07 Kao Corporation Blood fluidity improving agent
US7270837B2 (en) 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20070092454A1 (en) 2005-10-24 2007-04-26 Colgate-Palmolive Company Oral composition containing morin
CA2685031A1 (en) * 2007-03-19 2008-09-25 Atm Metabolics Lllp Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108627A1 (en) * 2001-09-25 2003-06-12 Jonathan Selzer Cranberry based dietary supplement and dental hygiene product
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOCHEM.J., vol. 386, JPN6012062444, 2005, pages 471 - 478, ISSN: 0002395466 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011001311A (ja) * 2009-06-19 2011-01-06 Pola Chemical Industries Inc 熱産生タンパク質発現促進剤
JP2017105745A (ja) * 2015-12-02 2017-06-15 共栄化学工業株式会社 皮膚外用剤

Also Published As

Publication number Publication date
CN101674821A (zh) 2010-03-17
EP2129371B1 (en) 2021-05-05
BRPI0809047B1 (pt) 2020-09-01
US7943164B2 (en) 2011-05-17
BRPI0809047B8 (pt) 2021-05-25
US20110118345A1 (en) 2011-05-19
US8198319B2 (en) 2012-06-12
MX2009009996A (es) 2010-01-20
EP2129371A1 (en) 2009-12-09
BRPI0809047A2 (pt) 2014-09-02
CA2685031A1 (en) 2008-09-25
CN101674821B (zh) 2013-06-26
US20080234364A1 (en) 2008-09-25
WO2008115723A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
US8198319B2 (en) Composition and method for treating diabetes and metabolic disorders
US7452549B2 (en) Synergistic antioxidant combination of delta tocols and polyphenols
US8962594B2 (en) Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia
KR100716799B1 (ko) 비만, 심혈관 질환 또는 관상동맥질환의 예방 및 치료용조성물
CN104869848B (zh) 用多酚增加黄烷-3-醇的生物利用度
US20120252887A1 (en) Composition and method for treating diabetes and metabolic disorders
KR101686777B1 (ko) 감잎 추출물을 포함하는 혈액순환 장애 또는 대사성 질환의 예방 또는 치료용 약학적 조성물
JP2008500322A (ja) 腫瘍性疾患及び炎症を治療するための医薬製品
US7833962B2 (en) Method of reducing hypertension by administering flavanol gylcosides
KR20110100882A (ko) 퀘르세틴을 유효성분으로 함유하는 지질대사 질환의 예방 또는 치료용 조성물
JP2010111600A (ja) 血流改善剤
KR20110100880A (ko) 퀘르세틴을 유효성분으로 함유하는 혈당 강하용 조성물
Dinelli et al. 8 Physiologically Bioactive Compounds of Functional Foods, Herbs, and Dietary Supplements
KR100708486B1 (ko) 섬유근육통증후군의 증상 개선 및 예방용 조성물
KR20230144935A (ko) 치커리 추출물, 늙은 호박 발효물 및 차전자피 분말을 유효성분으로 포함하는 기능성 식품 조성물
KR101397044B1 (ko) 아스테루빈의 신규 용도
JP2003501343A (ja) 血清高密度リポタンパク質濃度増大用バイオフラボノイド
Djazayery The role of flavonoids in cardiovascular disease: risk reduction, prevention and treatment.
Chakraborty et al. Promising Roles of Dietary Antioxidants in the Prevention of Certain Age-Related Diseases
Class et al. Patent application title: METHOD OF USING NUTRITIONAL COMPOUNDS DIHYDROQUERCETIN (TAXIFOLIN) AND ARABINOGALACTAN IN COMBINATION WITH DIHYDROQUERCETIN (TAXIFOLIN) TO REDUCE AND CONTROL CARDIOMETABOLIC RISK FACTORS ASSOCIATED WITH METABOLIC SYNDROME AND HYPERCHOLESTEROLEMIA Inventors: Sergey V. Philippov (Moscow, RU) Sergey V. Philippov (Moscow, RU) Igor M. Bogorodov (Moscow, RU) Igor M. Bogorodov (Moscow, RU) Assignees: FLAVITPURE, INC.
CN107456470A (zh) 一种膳食补充剂及其制备方法和应用
KR20160074852A (ko) 감잎 추출물을 포함하는 혈액순환 장애 또는 대사성 질환의 예방 또는 치료용 약학적 조성물
JP2004256430A (ja) アルドース還元酵素阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140428

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140527

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140725